Abstract
No. 425 Radiofrequency hyperthermia-enhanced local chemotherapy of esophageal squamous cancers Y. shi, F. Zhang, Z. Bai, J. Wang, L. Qiu, X. Yang; Radiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Radiology, University of Washington School of Medicine, Seattle, WA Purpose: To determine whether radiofrequency (RF) hyperthermia could enhance the therapeutic effect of cisplatin and 5-fluorouracil (5-FU) on esophageal squamous cancers (ESC). Materials and Methods: Human ESC cells (ESCC) were first labeled with red fluorescent protein (RFP) via a lentivirus transfection approach. For both in vitro confirmation and in vivo validation studies, RFP-ESCCs and 24 RFP-ESCengrafted mice were divided into four study groups with various treatments of (i) combination therapy with chemotherapy (cisplatin and 5-FU) plus MR imaging-heating-guidewire (MRIHG)-mediated local RF hyperthermia; (ii) chemotherapy only; (iii) RF hyperthermia only; and (iv) phosphate-buffered saline (PBS). In vitro cell proliferation was quantified by MTS assay, while in vivo validation with size changes of ESC masses and RFP-ESC signals among different treatment groups were monitored by ultrasound imaging and optical imaging over time with subsequent pathology correlation. Results: Of in vitro experiments, MTS assay demonstrated lowest cell proliferation of combination therapy compared to those of three control groups (23.4 7% VS 44.6 7.5% VS 95.8 2% VS 100 3%, po0.05). Of in vivo experiments, ultrasound imaging showed smaller tumor volumes with combination therapy than those with three control treatments (0.65 0.08 VS 1.27 0.04 VS 2.63 0.16 VS 2.71 0.19, Po0.05). Optical imaging demonstrated a decrease of RFPESC signals for the combination therapy group in comparison to those for three control groups (0.57 0.09 VS 1.37 0.17 VS 2.37 0.35 VS 2.54 0.35, Po0.05), which were well correlated with histologic confirmation. Conclusion: Local RF hyperthermia can enhance chemotherapeutic effect on human ESCs, which may open a new avenue for efficient management of esophageal malignancies. Educational Exhibit Abstract No. 426 Use of hands free gesture-based imaging control for vessel identification during hepatic transarterial chemoembolization and selective internal radiotherapy procedures Z.L. Bercu, V.V. Patil, R.S. Patel, E. Kim, S.F. Nowakowski, R.A. Lookstein, A.M. Fischman; Division of Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY Learning Objectives: 1. Understand the technical implementation of an inexpensive gesture-based input device for intra-procedural control of picture archiving and communications systems (PACS). 2. Understand the importance of vessel identification for transarterial chemoembolization (TACE) and selective internal radiotherapy (SIRT) procedures. 3. Understand how gesture-based device integration can lead to lower radiation doses to both the patient and operator through reduced need of angiograms. 4. Understand how gesture-based device integration can lead to faster, safer, and more accurate TACE and SIRT procedures. Background: TACE and MAA both require detailed appreciation for normal and variant hepatic anatomy. Identification of the cystic, gastric, gastroduodenal, falciform, and accessory arteries is critical to reduce the risk of nontarget chemoembolization or radiotherapy delivery. Patients may have variant anatomy difficult to deduce on angiography alone. Vessel identification is essential during subselective TACE and SIRT for complex disease. Use of CT/MRI is invaluable but often not available readily and delays case progression with the need to “scrub out.” The ability to review prior imaging in real-time in the angiosuite facilitates proper vessel identification, reduced need for radiation, and increased safety. Clinical Findings/Procedure Details: The Leap Motion Controller (Leap Motion, Inc., San Francisco, CA) allows for gesture mapping to input commands. It is inexpensive and Posters and Exhibits ’ JVIR S186 P os te rs an d Ex hi bi ts
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have